ArticleEClinicalMedicine2025
Global, regional, and national burdens of heart failure in adolescents and young adults aged 10-24 years from 1990 to 2021: an analysis of data from the Global Burden of Disease Study 2021.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association Between Vericiguat and Clinical Outcomes Across Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Reviews in cardiovascular medicine · 2026Pooled it
- The PREVENT Risk Equations and Cardiovascular Prevention in East Asia.Journal of atherosclerosis and thrombosis · 2026Review
- Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.European heart journal · 2026Article
- [Disease burden and risk factors of myocarditis among children and adolescents aged 0-19 years in China from 1990 to 2021 and projection of future disease burden trends].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Epidemiology of ischemic stroke in China and the United States: Global burden, temporal trends, and future projections.Medicine · 2026Article
- Diagnostic Tests for Stage B Heart Failure.Current cardiology reports · 2026Review
- Trends and projections of high body mass index-associated non-hodgkin lymphoma burden (1990-2040): A global burden of disease 2021 analysis.Annals of hematology · 2026Article
- Unequal patterns of tuberculosis in women of reproductive age: Insights from the Global burden of disease study 2021.Infectious medicine · 2026Article
- Post-LVAD cognitive trajectories and determinants of non-improvement in end-stage heart failure.Journal of thoracic disease · 2026Article
- Global burden of heart failure attributable to atrial fibrillation and flutter, insights from GBD 2021.ESC heart failure · 2026Article
- Arrhythmia-induced cardiomyopathy: focus on atrial fibrillation.Nature reviews. Cardiology · 2026Review
- Deep Learning-Based Automated Echocardiographic Measurements in Pediatric and Congenital Heart Disease.medRxiv : the preprint server for health sciences · 2026Article
- Heart Failure in Younger Adults in Africa: Evidence from the Ibadan Heart Failure Project.Research in heart yield and translational medicine · 2026Article
- Global, Regional, and National Burden and Trends of Hypertensive Heart Disease Among Women of Childbearing Age from 1992 to 2021.International journal of women's health · 2026Article
- Global, regional, and national burden of alopecia areata in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis.Frontiers in public health · 2026Article
- Global, regional, and national children and adolescent epilepsy burden, 1990-2021: an analysis based on the global burden of disease study 2021.Annals of medicine · 2025Article
- National Trends in Arrhythmias and Heart Failure Related Mortality in the United States From 1999 to 2023: A CDC Wonder Analysis.Journal of arrhythmia · 2025Article
- Factors associated with end-of-life quality in terminally ill cancer patients' last six months of life: a longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer.Breast cancer research and treatment · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prior studies suggest prevalence of heart failure (HF) has remained steady or progressively decreased over past 30 years in the general population. Whether this favourable trend occurred in adolescents and young adults aged 10-24 years has yet to be elucidated. We aim to identify the trends in the burden of HF in this young population from 1990 to 2021 to inform areas for targeted intervention and prevention efforts. Methods: We analyzed data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. The case number and rates per 100,000 population of prevalence and years lived with disability (YLDs) of HF at the global, regional, and national level in the population aged 10-24 years from 1990 to 2021 were reported. In addition, the HF trends by age, sex, and socio-demographic index (SDI) were analyzed. Furthermore, we calculated the average annual percentage changes (AAPC) and identified the year with the most pronounced changes in the trends with the joinpoint regression analysis. In detail, we divided the study population into three age groups: 10-14 years old, 15-19 years old, and 20-24 years old. We also employed the Bayesian age-period-cohort models (BAPC) to predict the future burden of HF up to 2030. Findings: Globally, the prevalence and YLDs rates of HF among adolescents and young adults in 2021 were 148.1 (95% uncertainty interval [UI]: 118.8-185.7) and 14.4 (9.2-21.2) per 100 000 population, increased from 125.5 (100.0-157.7) and 12.2 (7.8-17.8) in 1990 respectively. Noticeable changes in HF prevalence were found in 1994, 2001, 2004, 2010, and 2018. Regionally, East Asia had the most pronounced increase in HF prevalence rate (AAPC = 1.35 [1.28-1.43]) and YLDs rate (AAPC = 1.32 [1.27-1.38]), while the highest HF prevalence rates per 100,000 population were observed in High-income North America (232 [185.4-292]). The prevalence and YLDs of HF increased in most countries except Australia, Canada, and Spain. The largest increase in HF prevalence rate was observed in China (AAPC = 1.39 [1.31-1.48]). By SDI quintile, the middle-SDI quintile countries had the largest increase in prevalence and YLDs rates. By sex, males had a higher prevalence rate per 100,000 population than females (158.0 [95% UI: 126.7-198.9] vs 137.6 [95% UI: 110.0-172.2]) in 2021. Among three age groups, the largest increase in HF prevalence from 1990 to 2021 was found in individuals aged 20-24 years (AAPC = 0.61 [0.6-0.61]). Among all causes of HF, cardiomyopathy and myocarditis accounted for the highest proportion (32.7%) of prevalence cases of HF in 2021, followed by congenital birth defects (27.3%), and rheumatic heart disease (23.8%). The BAPC analysis predicted that the cases of HF prevalence and YLDs would show a rising trend from 2022 to 2030. Interpretation: The burden of HF in adolescents and young adults aged 10-24 years was still increasing globally, which may be obscured by the burden trend of general population. According to different underlying causes of HF, both high-income countries and low- and middle-income countries need to better prevent HF in adolescents and young adults. Funding: National Natural Science Foundation of China (grant 81900452) and Training Fund for Open Projects at Clinical Institutes and Departments of Capital Medical University (grant CCMU2022ZKYXY003).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.